EssilorLuxottica Expands in Med-Tech Sector
EssilorLuxottica has made significant strides in the med-tech sector through the acquisition of Ikerian and the launch of its Switch: Vision Innovation Summit.
The acquisition of Ikerian, under the RetinAI brand, aims to support eye care professionals in collecting and processing retinal images using AI, enabling more accurate and timely diagnosis and monitoring of eye disease progression.
- The RetinAI platform is FDA-cleared and CE-marked.
- It collects, processes, and grades retinal images and biomarker datasets.
- RetinAI Discovery applies AI models for early detection and monitoring of eye disease.
Leveraging its AI-powered analytics, we can turn clinical data into insights that enable faster, more accurate diagnoses and more effective disease monitoring.
Author's summary: EssilorLuxottica advances in med-tech with Ikerian acquisition.